TY - JOUR
T1 - HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status
AU - Anderson, Karen
AU - Dahlstrom, Kristina R.
AU - Cheng, Julia N.
AU - Alam, Rizwan
AU - Li, Guojun
AU - Wei, Qingyi
AU - Gross, Neil D.
AU - Chowell, Diego
AU - Posner, Marshall
AU - Sturgis, Erich M.
N1 - Funding Information: This study was supported by a research grant from the Early Detection Research Network (EDRN) U01CA117374 and Arizona State University Institutional funds (KSA), NIH/NCI R03 Grant CA128110-01A1 and CA016672 (EMS) and NCI R25T Grant CA57730 (Shine Chang, PhD, Principal Investigator) (KRD). Publisher Copyright: © 2015 Elsevier Ltd. All rights reserved.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Background Antibodies (Abs) to the HPV16 proteome increase risk for HPV-associated OPC (HPVOPC). The goal of this study was to investigate the association of a panel of HPV16 Abs with risk for OPC as well as the association of these Abs with tumor HPV and smoking status among patients with OPC. Methods IgG Abs to the HPV16 antigens E1, E2, E4, E5, E6, E7, L1, L2 were quantified using a programmable ELISA assay. Sera were obtained from 258 OPC patients at diagnosis and 250 healthy controls. HPV16 tumor status was measured by PCR for 137 cases. Multivariable logistic regression was used to calculate odds ratios for the association of HPV16 Abs with risk for OPC. Results HPV16 E1, E2, E4, E5, E6, E7 and L1-specific IgG levels were elevated in OPC patients compared to healthy controls (p < 0.05). After multivariable adjustment, Ab positivity for NE2, CE2, E6, and/or E7 was associated with OPC risk (OR [95% CI], 249.1 [99.3-624.9]). Among patients with OPC, Ab positivity for these antigens was associated with tumor HPV status, especially among never or light smokers (OR [95% CI], 6.5 [2.1-20.1] and OR [95% CI], 17.5 [4.0-77.2], respectively). Conclusions Antibodies to HPV16 proteins are associated with increased risk for HPVOPC. Among patients with OPC, HPV16 Abs are associated with tumor HPV status, in particular among HPV positive patients with no or little smoking history.
AB - Background Antibodies (Abs) to the HPV16 proteome increase risk for HPV-associated OPC (HPVOPC). The goal of this study was to investigate the association of a panel of HPV16 Abs with risk for OPC as well as the association of these Abs with tumor HPV and smoking status among patients with OPC. Methods IgG Abs to the HPV16 antigens E1, E2, E4, E5, E6, E7, L1, L2 were quantified using a programmable ELISA assay. Sera were obtained from 258 OPC patients at diagnosis and 250 healthy controls. HPV16 tumor status was measured by PCR for 137 cases. Multivariable logistic regression was used to calculate odds ratios for the association of HPV16 Abs with risk for OPC. Results HPV16 E1, E2, E4, E5, E6, E7 and L1-specific IgG levels were elevated in OPC patients compared to healthy controls (p < 0.05). After multivariable adjustment, Ab positivity for NE2, CE2, E6, and/or E7 was associated with OPC risk (OR [95% CI], 249.1 [99.3-624.9]). Among patients with OPC, Ab positivity for these antigens was associated with tumor HPV status, especially among never or light smokers (OR [95% CI], 6.5 [2.1-20.1] and OR [95% CI], 17.5 [4.0-77.2], respectively). Conclusions Antibodies to HPV16 proteins are associated with increased risk for HPVOPC. Among patients with OPC, HPV16 Abs are associated with tumor HPV status, in particular among HPV positive patients with no or little smoking history.
KW - Antibodies
KW - Biomarker
KW - HPV
KW - Head and neck cancer
KW - Oropharyngeal cancer
KW - Serology
UR - http://www.scopus.com/inward/record.url?scp=84930634108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930634108&partnerID=8YFLogxK
U2 - 10.1016/j.oraloncology.2015.04.011
DO - 10.1016/j.oraloncology.2015.04.011
M3 - Article
C2 - 25957822
SN - 1368-8375
VL - 51
SP - 662
EP - 667
JO - Oral Oncology
JF - Oral Oncology
IS - 7
ER -